Lipum AB (publ) (STO:LIPUM)

Sweden flag Sweden · Delayed Price · Currency is SEK
13.95
+0.05 (0.36%)
Feb 5, 2026, 4:31 PM CET
-1.06%
Market Cap295.91M +1.8%
Revenue (ttm)n/a
Net Income-76.37M
EPS-3.60
Shares Out21.21M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,000
Average Volume194,230
Open13.95
Previous Close13.90
Day's Range13.90 - 13.95
52-Week Range8.56 - 21.20
Beta0.25
RSI37.45
Earnings DateFeb 25, 2026

About Lipum AB

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. The company develops SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. It has a collaboration with NorthXBiologies for production of SOL-116 setatt; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol LIPUM
Full Company Profile

Financial Performance

Financial Statements